Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients With Metastatic Colorectal or Metastatic Breast Cancer
Patients with metastatic colorectal or breast cancer will be recruited.
- Metastatic Colorectal Cancer: capecitabine alone or capecitabine + oxaliplatin for 8
- Metastatic Breast Cancer: capecitabine alone or capecitabine + docetaxel for 8 3-week
All patients will be given a mobile phone onto which they will enter any side-effects
experienced prior to taking capecitabine in the morning and evening. Any grade 3 or 4
symptoms will trigger an alert to a pager held by the ward-staff for immediate attention.
Thus, patients' severe side-effects will be monitored in real time and the trial will allow
real-time dose reductions during cycles and dose-increases at clinics. Patient experience in
the trial will also be evaluated during their participation in the trial.
Patients will already be receiving the drug prior to this study and will not be administered
to patients as part of this study.
Observational Model: Cohort, Time Perspective: Prospective
Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)
At the end of each cycle and at occurrence
Oxfordshire research ethics committee A, country name: United Kingdom